Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(2S)-4-(4-fluorobenzyl)-N-(3-sulfanylpropyl)piperazine-2-carboxamide is a synthetic small molecule belonging to the class of alpha amino acid amides. It features a piperazine core substituted with a 4-fluorobenzyl group and an N-linked 3-sulfanylpropyl chain. The compound has been cataloged in chemical and drug databases as an experimental molecule but does not have any known clinical use or approved indications. Its mechanism of action, biological targets, pharmacological activity, and therapeutic potential are not described in the available literature[1][7]. There is no evidence it has advanced beyond preclinical or early experimental status.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2S)-4-(4-fluorobenzyl)-N-(3-sulfanylpropyl)piperazine-2-carboxamide.